Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2023-06-19 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于“灵康转债“2023年跟踪评级结果的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the 2023 follow-up credit rating results for a convertible bond issued by Lingkang Pharmaceutical Group Co., Ltd. It includes details about the previous and current credit ratings and references a detailed rating report published on the Shanghai Stock Exchange website. The document is short (889 characters) and primarily serves to inform about the rating update rather than providing the full rating report itself. It does not contain financial statements or detailed financial data. Therefore, it fits best as a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-06-19 Chinese
灵康药业集团股份有限公司主体及“灵康转债”2023年度跟踪评级报告
Regulatory Filings
2023-06-19 Chinese
关于召开2022年度暨2023年第一季度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement about the scheduling and details of a performance explanation meeting (业绩说明会) for the 2022 annual and 2023 first quarter results. It specifies the meeting time, location, participants, and how investors can submit questions and attend. It references that the 2022 annual report and 2023 first quarter report have already been disclosed on the stock exchange website. The document does not contain actual financial data or detailed financial analysis but serves to inform investors about the upcoming conference call or presentation. This matches the definition of a Call Transcript (CT) precursor or an Investor Presentation (IP) event announcement. However, since it is an announcement of the meeting rather than the transcript or presentation itself, and given the short length (1400 characters), it is best classified as an Investor Presentation (IP) type document, as it focuses on financials, strategy, and market position discussion with investors.
2023-06-14 Chinese
2022年年度股东大会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2022 Annual General Meeting (AGM) of Lingkang Pharmaceutical Group Co., Ltd. It discusses the convening, procedures, qualifications of attendees, and voting results of the AGM. The document does not contain financial statements or detailed financial performance data, nor is it an announcement of the AGM or voting results. Instead, it is a legal opinion on the AGM process and results. This type of document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to the official validation and legal opinion on the AGM voting process and results.
2023-05-24 Chinese
灵康药业集团股份有限公司公开发行A股可转换公司债券受托管理事务报告（2022年度）
Audit Report / Information Classification · 95% confidence The document is titled as a "债券受托管理事务报告" (Bond Trustee Management Report) for the year 2022, related to the public issuance of A-share convertible corporate bonds by 灵康药业集团股份有限公司. It contains detailed information about the bond issuance, terms, bondholder meetings, bond interest payments, bond rating updates, and the issuer's annual operating and financial conditions. It also includes audit report references and financial data for 2022. The document is comprehensive and focused on the bond trustee management activities and the bond issuance details rather than a general annual report or earnings release. This type of document fits best under the category of Audit Report / Information (AR), as it is a standalone report related to bond issuance, trustee duties, and financial audit information, but it is not a full Annual Report (10-K) or an Interim/Quarterly Report (IR). FY 2022
2023-05-24 Chinese
2022年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2022 Annual General Meeting Resolution Announcement" for Lingkang Pharmaceutical Group Co., Ltd. It details the date and location of the AGM, attendance, voting results on various proposals including the 2022 annual reports, financial statements, profit distribution plan, and other corporate matters. The document is a formal announcement of the resolutions passed at the AGM, including voting outcomes, rather than the full annual report or financial statements themselves. The length is under 5,000 characters and it primarily reports on the meeting and voting results. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2023-05-24 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.